ClinicalTrials.gg
CompletedNCT00651274Updated Aug 15, 2024

Comparison of Co-administration of Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Primary Hypercholesterolemia (P03476)

A Phase 4 interventional study of Ezetimibe and Placebo in Atherosclerosis, Hypercholesterolemia and Coronary Heart Disease, sponsored by Organon and Co. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-08-15.

Sponsored by Organon and Co · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 11 months after the study started (first participant enrolled Apr 2003, registered Mar 2008).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing ezetimibe in Atherosclerosis — 2 open to participants now, 2 under way, none of them phase 3. Ezetimibe · Atherosclerosis.

Enrollment
9th of 22
144 · median 121
Started
2003
with 7 others
Phase 4
9 of 22
1 open now
Registered
8th of 22
by date
Lead sponsor
11 of 22
Organon and Co

Among the 22 studies testing ezetimibe in Atherosclerosis, this one is the 9th largest by enrollment, is one of 8 that started in 2003, is one of 9 in phase 4, and was the 8th registered.

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.

Browse Atherosclerosis studies →

Open to participants now

2 of the 22 studies testing ezetimibe in Atherosclerosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ezetimibe

Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 163 Atherosclerosis studies recruiting now, 85 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing ezetimibe in Atherosclerosis, or all of them as a file.
02

Study summary

This study will assess whether the daily co-administration of ezetimibe 10 mg with ongoing treatment of simvastatin 20 mg will be more effective than treatment with simvastatin 20 mg alone in further reducing LDL-C concentrations.

03

Conditions studied

  • Atherosclerosis
  • Hypercholesterolemia
  • Coronary Heart Disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must demonstrate their willingness to participate in the study and comply with its procedures by signing a written .
  • Subjects must be >= 18 years and \<= 75 years of age.
  • Subjects must have an LDL-C concentration >= 2.6 mmol/L (100 mg/dL) to \<= 4.1 mmol/L (160 mg/dL) using the Friedewald calculation available at the time of randomization Visit 3 (Baseline Visit).
  • Subjects must have triglyceride concentrations of \< 3.99 mmol/L (350 mg/dL) at Visit 3 (Baseline Visit).
  • Subjects must have documented coronary heart disease (CHD). For the purposes of this study, CHD will include one or more of the following features: documented stable angina (with evidence of ischemia on exercise testing); history of myocardial infarction; history of percutaneous coronary intervention (primarily PTCA with or without stent placement); symptomatic peripheral vascular disease (claudication); documented history of atherothrombotic cerebrovascular disease; and/or documented history of unstable angina or non-Q wave myocardial infarction.
  • Subject must be currently taking simvastatin 20 mg daily and by history has taken 80% of daily evening doses for the preceding 6 weeks prior to Visit 3 (Baseline Visit).
  • Subjects must have liver transaminases (, AST) \< 50% above the , with no active liver disease, and CK \< 50% above the upper limit of normal at Visit 3 (Baseline Visit).
  • Clinical laboratory tests (CBC, blood chemistries, urinalysis) must be within normal limits or clinically acceptable to the investigator at Visit 3 (Baseline Visit).
  • Subjects must have maintained a cholesterol lowering diet program for at least 4 weeks prior to the study and be willing to continue the same diet program during the study.
  • Subjects must report a stable weight history for at least 4 weeks prior to entry into study at Visit 3 (Baseline Visit).
  • Women receiving hormonal therapy, including hormone replacement, any estrogen antagonist/agonist, or oral , must have been maintained on a stable dose and regimen for at least 8 weeks and be willing to continue the same regimen for the duration of the study.
  • Women of (includes women who are less than 1 year and women who become sexually active) must be using an acceptable method of birth control (e.g., hormonal contraceptive, medically prescribed IUD, condom in combination with spermicide) or be surgically sterilized (e.g., hysterectomy or tubal ligation).
  • Subjects must be free of any diseases other than hyperlipidemia or coronary heart disease that would interfere with study evaluations.
  • Subjects must understand and be able to adhere to the dosing and visit schedules, and must agree to remain on their cholesterol-lowering diet and their exercise regimen for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • Subjects whose (BMI) is >= 30 Kg/m\^2 at Visit 3 (Baseline Visit).
  • Subjects who consume > 14 alcoholic drinks per week. (A drink is: a can of beer, glass of wine, or single measure of spirits).
  • Any condition or situation which, in the opinion of the investigator, might pose a risk to the subject or interfere with participation in the study.
  • Women who are pregnant or nursing.
  • Subjects who have not observed the designated for any of the prohibited medications
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
144 participants (actual)

Study arms

  • Experimental
    Ezetimibe

    Drug: Ezetimibe

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • oral tablets: ezetimibe 10 mg once daily for 6 weeks (plus continued simvastatin)

    Also known as: SCH 58235

  • DrugPlacebo

    oral tablets: placebo to match ezetimibe 10 mg once daily for 6 weeks (plus continued simvastatin)

06

What researchers measure

Primary outcomes

  1. Percent change from baseline in LDL-cholesterol with ezetimibe added to simvastatin versus continued simvastatin alone.

    Time frame: 6 weeks

Secondary outcomes

  1. Percentage of subjects who achieve target LDL-C as defined by the ESC or NCEP guidelines with ezetimibe added to simvastatin versus continued simvastatin alone

    Time frame: 6 weeks

  2. Percent change from baseline in total cholesterol, HDL-C and triglycerides with ezetimibe added to simvastatin versus continued simvastatin alone.

    Time frame: 6 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Zubaid M, Shakir DK, Bazargani N, Binbrek A, Gopal R, Al-Tamimi O, Bakir S. Effect of ezetimibe coadministration with simvastatin in a Middle Eastern population: a prospective, multicentre, randomized, double-blind, placebo-controlled trial. J Cardiovasc Med (Hagerstown). 2008 Jul;9(7):688-93. doi: 10.2459/JCM.0b013e3282f3a1b1. PubMed 18545068 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2003 to primary completion in Aug 2004, 16 months.

Of 55 phase 4 interventional studies under Atherosclerosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 59. This study's 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2008
First posted
Apr 2, 2008
StartActual
Apr 1, 2003
Primary completionActual
Aug 1, 2004
CompletionActual
Aug 1, 2004
Last update
Aug 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00651274
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Apr 2, 2008
Start date
Apr 1, 2003
Primary completion
Aug 1, 2004
Completion
Aug 1, 2004
Last update
Aug 15, 2024

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ezetimibe

Start the discussion